Mayo Clinic researchers have shown that approved thyroid cancer drugs can restore a key antigen on aggressive tumour cells, making them visible once more to CAR T cells and improving treatment ...

City of Hope researchers have developed a modular 'plug-and-play' CAR T-cell platform that enables post-infusion ...

Luca Lotta, MD, PhD, is Vice President and Chief Translational Genetics Officer at the Regeneron Genetics Center (RGC), where ...

Scientists at National Jewish Health have identified oestrogen receptor alpha as a potential therapeutic target for ...

Finding the right drug target remains one of discovery's biggest challenges. Human genetics is helping researchers strengthen ...

Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for ...

Combining the BCG vaccine with a B-cell-targeting immunotherapy significantly reduced tuberculosis relapse rates in ...

Dr Garegin Papoian is Co-founder and Chief Scientific Officer at Deep Origin, where he leads the development of hybrid AI-mechanistic drug discovery models. Previously a Monroe Martin Professor at the ...

Insilico Medicine has published a Cell cover study introducing LongevityBench, a suite of specialised AI models and an ...

UK-based cancer drug discovery company Big Picture Bio has closed £2.2 million in funding to advance AI-designed combination ...

Virtual screening can assess billions of compounds, but performance can fall on unfamiliar targets. Combining AI with ...